Lisdexamfetmine's Effect In ADHD
We are actively recruiting teens and young adults ages 12-25 for the LEIA study. This research study is an Approved Drug Trial. Lisdexamfetamine (VyvanseÂ®) is approved by the Food and Drug Administration (FDA) for treating Attention Deficit-Hyperactivity Disorder in children, adolescents and adults. The purpose of this type of study is to collect more information about the ways Lisdexamfetamine effects how teens and young adults with ADHD make decisions, relating to real world outcomes.
After an initial screening visit, participants are randomly selected to begin receiving either Lisdexamfetamine (VyvanseÂ®) or a placebo (sugar pill) for the next 9 weeks. Physicians will monitor symptoms, safety, and choose doses based on how each person responds to the medication. Weekly appointments are approximately 1-2 hours long at the UC Davis Medical Center in Sacramento. Participation in this study can last up to 15 weeks including the screening and washout period.
Compensation is $50 for each fMRI scan and $10 for each other visit, totaling $190 for the whole study. At the end of the study, participants also receive the results of any IQ and Academic testing completed as well as feedback from the physician on efficacy of treatment and, if applicable, optimal dose. There are no costs for receiving the study drug or physician visits in this study.
If you have questions, or would like to participate, please contact the research team:
Erin Calfee and Arthur Hartanto
LEIA Study Coordinators
2825 50th Street, Sacramento, CA 95817
PI: Julie Schweitzer, Ph.D., UC Davis